Eko, a digital health company applying artificial intelligence (AI) to address heart and lung disease, has launched the SENSORA Cardiac Disease Detection Platform.
The SENSORA platform features AI that identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.
SENSORA is a cardiovascular disease detection platform that combines the latest advancements in applied machine learning with the stethoscope. By capturing and analyzing heart sounds and electrical signals with its digital stethoscopes, Eko has pioneered a detection platform designed to expand as the company develops applications for additional cardiac conditions.
Further reading: Cardiovascular Disease Diagnostics and Testing
“Our vision for SENSORA is to make cardiovascular disease detection simple and accurate in frontline care settings like primary care and urgent care,” says Connor Landgraf, co-founder & CEO of Eko. “During a routine physical exam, patients can now have access to advanced structural murmur detection and arrhythmia assessment by their primary care physician in seconds, making early intervention possible for millions of patients with silent cardiovascular disease. We are making the world’s most universal medical exam objective and accurate.”
SENSORA FDA-cleared structural murmur detection helps health systems more accurately and consistently identify valvular heart disease (VHD) in patients during a routine visit with their primary care physician.
VHD can lead to heart failure, stroke, blood clots, and death. Older adults have a 1 in 10 chance of developing clinically significant VHD. However, more than half (57%) of clinically significant valvular heart disease goes undetected in this population.
SENSORA Care Pathway Analytics follows patients with identified structural murmurs through the care continuum, providing downstream visibility into patient flows, clinical outcomes, and patient economics. Care Pathway Analytics is designed to assist with critical decision-making by identifying care gaps that can be transformed into improved operational efficiencies, including reduced delays in delivery of care, length of stay, and readmission rates, the company says.
“The primary care setting is a patient’s first line of defense for identifying and diagnosing heart disease,” says John Chorba, MD, assistant professor in residence, Division of Cardiology, Zuckerberg San Francisco General Hospital and Department of Medicine, University of California San Francisco. “However, we know from clinical evidence that detection rates are low. The SENSORA platform promises to better serve patients by increasing the accuracy and consistency of structural murmur identification and improving patients’ lives by getting them into treatment earlier.”
In addition to Eko’s current portfolio of five FDA 510(k) cleared digital solutions, the company has two novel machine learning algorithms in development that apply electrocardiogram (ECG) and heart sound data: a low ejection fraction detection algorithm (named “ELEFT”) to detect a weakened heart pump, which is present in half of heart failure patients, and an algorithm to detect and stratify pulmonary hypertension.
